NCT07225634尚未招募3 期
An Open Label, Pharmacokinetic and Safety Study of Combogesic® IV in Pediatric Patients With Acute Pain
AFT Pharmaceuticals, Ltd.2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2026年9月1日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- The incidence of treatment-emergent adverse events (TEAEs) associated with exposure to Combogesic® IV in pediatric patients
研究概览
简要总结
Combogesic® IV is an intravenous medicine (given by vein) containing a combination of two pain relief (analgesic) medicines called ibuprofen and acetaminophen. The goal of this clinical trial is to study the way that the body processes and clears the intravenous infusion of Combogesic® IV and that it is safe to be used in children and adolescents between the ages of 2 and <17 years.
What will the study involve for participants?
- Combogesic® IV will be administered every 6 hours as necessary with a maximum of 4 doses within a 24-hour period as an intravenous infusion for about 15 minutes.
- Participants will receive Combogesic® IV for a minimum of 12 hours (2 doses) up to a maximum of 5 days (20 doses). Dosing will be dependent on body weight.
- If pain is not sufficiently controlled by Combogesic® IV, opioids may be used as supplementary pain relief at the discretion of the study doctor.
- Have their blood samples collected before dosing and at specific times after dosing. The amount of study drug in the blood will be measured, and safety assessments (including blood and urine samples) will be done.
- Rate the study drug at the end of the treatment.
It is expected that Combogesic® IV will be well tolerated in children and adolescents and that the pharmacokinetics findings will be similar as compared with adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 16 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Is male or female aged between 2 and <17 years.
- •Have a clinical indication of acute pain* requiring hospitalization and multiple doses of parenterally administered nonopioid analgesic medication for at least 0.5 - 5 days.
- •Is either able to provide written informed consent or consent is provided from parents/legal guardians and assent provided from participants (where appropriate).
- •Is willing and able to remain at the study site for at least 12 hours and to attend a follow-up visit at 7 ± 2 days after the last dose of study drug.
- •Have negative HIV and hepatitis B & C test results.
- •Acute pain indications may include but are not limited to post-operative pain associated with musculoskeletal or soft tissue surgery, fractures or injury, or medical procedures.
排除标准
- •Has a known history of allergic reaction or clinically significant intolerance to acetaminophen, aspirin, opioids, or any nonsteroidal anti-inflammatory drugs (NSAIDs, including ibuprofen); history of NSAID-induced bronchospasm (subjects with the triad of asthma, nasal polyps, and chronic rhinitis are at greater risk for bronchospasm and should be considered carefully); or hypersensitivity, allergy, or significant reaction to sulfa (including sulfonamide) medicines, ingredients of the study drug, or any other drugs used in the study including anesthetics and antibiotics that may be required.
- •Has experienced any surgical complications or other issues that, in the opinion of the Investigator, could compromise the safety of the subject if he or she participates in the study or could confound the results of the study.
- •Has any clinically significant unstable cardiac, respiratory, neurological, immunological, hematological, or renal disease or any other condition that, in the opinion of the Investigator, could compromise the subject's welfare, ability to communicate with the study staff, or otherwise contraindicate study participation.
- •Has a history or current diagnosis of a significant psychiatric disorder that, in the opinion of the Investigator, would affect the subject's ability to comply with the study requirements.
- •Has a history of a clinically significant (Investigator opinion) gastrointestinal (GI) event within 6 months before screening or has any history of peptic or gastric ulcers or GI bleeding.
- •Has a surgical or medical condition of the GI or renal system that might significantly alter the absorption, distribution, or excretion of any drug substance.
- •Is considered by the Investigator, for any reason to be an unsuitable candidate to receive the study drug.
- •Is receiving systemic chemotherapy, has an active malignancy of any type, or has been diagnosed with cancer within 5 years before Screening (excluding treated squamous or basal cell carcinoma of the skin).
- •Is currently receiving anticoagulants (e.g. heparin or warfarin).
- •Has received a course of systemic corticosteroids (either oral or parenteral) within 3 months before screening (inhaled nasal steroids and regional/limited area application of topical corticosteroids (Investigator discretion) are allowed).
- •Has a history of chronic use (defined as daily use for > 2 weeks) of NSAIDs, opiates, or glucocorticoids (except inhaled nasal steroids and regional/limited topical corticosteroids), for any condition within 6 months before study drug administration. Aspirin at a daily dose of ≤ 325 mg is allowed for cardiovascular prophylaxis if the subject has been on a stable dose regimen for ≥ 30 days before screening and has not experienced any relevant medical problem.
- •Has a significant renal or hepatic disease, as indicated by clinical laboratory assessment (results ≥ 3 times the upper limit of normal [ULN] for any liver function test, including aspartate aminotransferase [AST], alanine aminotransferase [ALT], or creatinine ≥ 1.5 times the ULN).
- •Has any clinically significant laboratory finding at screening that, in the opinion of the Investigator, contraindicates study participation.
- •Participated in another clinical study within 30 days before Screening.
- •Pregnant or lactating females
- •Sexually active females of childbearing potential not using adequate contraception and sexually active males not using adequate contraception
研究组 & 干预措施
Combogesic® IV
Experimental
Combogesic® IV (acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion), will be administered by injection into a dedicated indwelling venous cannula, infused over 15 minutes every 6 hours
干预措施: Combogesic® IV (fixed-dose combination containing acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion) (Drug)
结局指标
主要结局
The incidence of treatment-emergent adverse events (TEAEs) associated with exposure to Combogesic® IV in pediatric patients
时间窗: From start of exposure to Combogesic® IV up to 7 days after last dose
TEAEs occurring at any timepoint during the treatment period will be coded to MedDRA System Organ Class Code and Preferred Term and tabulated as frequencies and percentages.
次要结局
- The time course of treatment-emergent adverse events(From start of exposure to Combogesic® IV up to 7 days after last dose)
- The incidence of treatment-related adverse events(From start of exposure to Combogesic® IV up to 7 days after last dose)
- The incidence of treatment-emergent adverse events of interest (cardiovascular, gastrointestinal, renal, hepatic, administration site conditions and bleeding-related events)(From start of exposure to Combogesic® IV up to 7 days after last dose)
- Changes in heart rate(From baseline up to 7 days after last dose of Combogesic® IV)
- Changes in biochemistry values (Aspartate transaminase)(From baseline up to 7 days after last dose)
- Patient's global evaluation of the study drug(From Day 1 until completion of treatment period up to 5 days.)
- Define the pharmacokinetic parameters of Combogesic® IV (Cmax - Maximum measured plasma concentration)(Pre-dose of Combogesic® IV to 6 hours post infusion)
- Consumption of supplemental opioid medication in each 24-hour period as Morphine Milligram Equivalent (MME).(From start of exposure to Combogesic® IV until up to 5 days)
- Define the pharmacokinetic parameters of Combogesic® IV (Tmax - Time of maximum measured plasma concentration)(Pre-dose of Combogesic® IV to 6 hours post infusion)
- Define the pharmacokinetic parameters of Combogesic® IV ( t½ - Time required for the plasma drug concentration to decrease by one half)(Pre-dose of Combogesic® IV to 6 hours post infusion)
- Define the pharmacokinetic parameters of Combogesic® IV (AUC(0-t) - The area under the plasma concentration versus time curve from time zero to the last measurable concentration)(Pre-dose of Combogesic® IV to 6 hours post infusion)
- Define the pharmacokinetic parameters of Combogesic® IV (Extrapolated AUC(0-∞)- The area under the plasma concentration versus time curve, from zero to infinity)(Pre-dose of Combogesic® IV to 6 hours post infusion)
- Changes in blood pressure(From baseline up to 7 days after last dose of Combogesic® IV)
- Changes in body temperature(From baseline up to 7 days after last dose of Combogesic® IV)
- Changes in respiratory rate(From baseline up to 7 days after last dose of Combogesic® IV)
- Changes in hematology values (Hemaglobin)(From baseline up to 7 days after last dose)
- Changes in hematology values (Hematocrit)(From baseline up to 7 days after last dose)
- Changes in hematology values (Platelet count)(From baseline up to 7 days after last dose)
- Changes in hematology values (Red Blood Cell (RBC) count)(From baseline up to 7 days after last dose)
- Changes in hematology values (White Blood Cell (WBC) count)(From baseline up to 7 days after last dose)
- Changes in hematology values (Differential Leukocyte Count (DLC))(From baseline up to 7 days after last dose)
- Changes in biochemistry values (Sodium)(From baseline up to 7 days after last dose)
- Changes in biochemistry values (Potassium)(From baseline up to 7 days after last dose)
- Changes in biochemistry values (Urea)(From baseline up to 7 days after last dose)
- Changes in biochemistry values (Creatinine)(From baseline up to 7 days after last dose)
- Changes in biochemistry values (Phosphate)(From baseline up to 7 days after last dose)
- Changes in biochemistry values (Glucose)(From baseline up to 7 days after last dose)
- Changes in biochemistry values (Albumin)(From baseline up to 7 days after last dose)
- Changes in biochemistry values (Total protein)(From baseline up to 7 days after last dose)
- Changes in biochemistry values (Alkaline phosphates)(From baseline up to 7 days after last dose)
- Changes in biochemistry values (Gamma-glutamyl transferase)(From baseline up to 7 days after last dose)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered AloneHealthyNCT01662674LG Life Sciences27
已完成
1 期
To Evaluate the Safety and PK Characteristics in Healthy VolunteersHealthyNCT06355349JW Pharmaceutical46
已完成
1 期
To Evaluate the Safety and PK Characteristics in Healthy Volunteers-JW24107NCT06816719JW Pharmaceutical47
Unknown
1 期
The Drug Interaction of DWP16001 and DWC202010 After Oral Administration in Healthy AdultsHealthy VolunteersNCT05321732Daewoong Pharmaceutical Co. LTD.24
Unknown
1 期
A Safety, Tolerability, Pharmacokinetic, and Efficacy Study of Docetaxel InjectionConcentrate for Nano-Dispersion (DICN) in Subjects With Lung Cancer (NSCLC)CTRI/2012/06/002736Sun Pharma Advanced Research Company Ltd30